ZW-191

N/A

Report date: 2026/02/06 20:01:23

Base Information

Drug NameZW-191
Drug Alias NameZW-191
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase I inhibitorsFolate receptor alpha antagonists
TargetsDNA topoisomerase IFolate receptor alpha
Therapy Area/IndicationsSolid tumoursGenital Neoplasms, FemaleCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeAustralia +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesZymeworks Inc
China Registration ClassN/A

Develop Information

Active CompaniesZymeworks IncZymeworks BC Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursGenital Neoplasms, FemaleCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A